Small Animal Patients Needed for Clinical Studies – December 2023

The following clinical studies are recruiting patients at UW Veterinary Care. For more information, please visit our Website or contact Amy Elbe, CVT, LAT, Clinical Research Technician, at 608-890-3484. Thank you for helping improve the health of animals.

- **Cardiology**
  - Participant in the Dog Aging Project Trial of Rapamycin in Aging Dogs (TRIAD) Study

- **General Surgery**
  - Dogs undergoing surgery for Laryngeal Paralysis – evaluate EMG and stimulation responsiveness

- **Genetics – investigating genetic heritability**
  - Cats over 12 years with no history of Feline Oral Resorptive Lesions
  - Newfoundlands & Golder Retrievers with non-contact Cranial Cruciate Rupture. Newfoundlands 5 years and older without a history of cruciate disease.
  - Irish Wolfhounds with Osteosarcoma at 5 years or younger and Irish Wolfhounds 10 years and older without a history of osteosarcoma.
  - Dogs (any breed) 8 years or older with Laryngeal Paralysis.

- **Internal Medicine**
  - Dogs with newly diagnosed ITP - investigation of changes in cytokines during treatment
  - Dogs with Stage II, III, and IV chronic kidney disease – investigate if Doxycycline or Clavamox are passed in the urine in dogs with kidney disease in the same concentrations as dogs without kidney disease.
  - Cats with FIP (feline infectious peritonitis) – investigate the efficacy of in-hospital treatment of FIP.
  - Healthy Boxer dogs and Boxer dogs with Lymphoma – investigate environmental risk factors of affected dogs and healthy age/sex matched dogs.

- **Neurology**
  - Dogs with Meningoencephalitis of Unknown Etiology (MUE) – evaluate 2 treatment medication protocols
  - Cats 12 years and older being euthanized - investigate neurologic, ophthalmic, and behavioral changes

- **Oncology**
  - Dogs with solid tumors 2cm-8cm (excluding mast cell, hemangiosarcoma, lymphoma, thyroid carcinomas) - evaluate shingrix/gardasil vaccine OR rabies vaccine paired with intra-tumoral injections as new treatment.
  - Dogs with Oral Melanoma, stage III – Evaluate new medication
  - Dogs with Malignant Melanoma (except malignant melanoma on the lip only) – Evaluate new medication
  - Dogs with primary pulmonary tumors or 1-3 metastatic pulmonary lesions– Pilot study to evaluate Synchrony technology for tumors that may move during treatment.
  - Dogs on CHOP for Lymphoma evaluate Visbiome Probiotic vs Metronidazole for diarrhea
  - Dogs with diffuse large cell B cell lymphoma - evaluate the DNA of dogs enrolled through blood testing and lymph node biopsy. These patients must go through traditional CHOP protocol.
  - Dogs with Metastatic Cancer that has an accessible tumor >2cm (except mast cell tumor & hemangiosarcoma) – evaluate an intravenous, targeted radiation treatment combined with an immunotherapy treatment
  - Dogs with Lymphoma or Non-Sarcomatous Solid tumors – evaluate the effectiveness and tolerability of 2 new anti-cancer agents.
  - Healthy Boxer dogs and Boxer dogs with Lymphoma – investigate environmental risk factors of affected dogs and healthy age/sex matched dogs.

- **Ophthalmology**
  - Dogs being euthanized for reasons other than eye disease – look at post-mortem changes
  - Dogs diagnosed with SARDS – evaluate clotting system in dogs with SARDS to see if related to vision loss
  - Cairn Terriers of any age with Ocular Melanosis or Cairn Terriers over 12 yrs without ocular melanosis.
  - Huskies/Entlebucher Mt Dogs 10+ years old or with a history of glaucoma – investigate genetic basis of glaucoma